Metropolis Healt (METROPOLIS)

FairStock Score: 51/100 — MIXED

Score breakdown: P/E: 0/3 · ROCE: 1/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Low leverage with debt/equity of 0.15 and Piotroski F-Score of 8/9 indicate strong financial health.
• Altman Z-Score of 5.36 suggests low bankruptcy risk.
• Promoter holding of 48.88% aligns management interests with shareholders.
• Sales growth of 18.95% and latest quarter net profit of ₹42 Cr on ₹406 Cr sales show continued expansion.
• ROCE of 14.66% and ROE of 12.64% reflect reasonable capital efficiency.

Concerns

• Valuation is expensive: P/E of 56.44 and EV/EBITDA of 52.99 leave little room for error.
• Price of ₹472.35 is above the Graham Number of ₹435.13, so traditional margin of safety is absent.
• Profit growth of 10.52% lags sales growth of 18.95%, indicating margin pressure.
• Free cash flow of ₹64 Cr and dividend yield of 0.21% offer minimal cash return to shareholders.

AI Analysis

At first glance, Metropolis has the profile of a decent fast-growing healthcare services firm. The financial health is genuinely good: debt/equity just 0.15, Piotroski score 8/9, Altman Z-score 5.36. Promoter holding of 48.88% means owners have serious skin in the game. Sales growth of 18.95% and latest quarter revenue of ₹406 Cr with ₹42 Cr profit show the franchise is expanding and still converting revenue into earnings. ROE and ROCE of 12.64% and 14.66% are acceptable, though not exceptional. Positive free cash flow of ₹64 Cr adds to the comfort. But as value investors, we must pay a reasonable price. At ₹472.35, the P/E is 56.44 and EV/EBITDA is 52.99. That is a rich multiple for any business, and it already assumes many years of smooth compounding. The Graham Number of ₹435.13 is below the current price, so I see no traditional margin of safety. The DCF figure of ₹655.86 is comforting, but DCFs are only as good as their assumptions; I would rather err on the side of Graham's discipline. I am also bothered that profit growth of 10.52% is well behind sales growth of 18.95%; that suggests operating costs or competition are consuming the incremental revenue. With a dividend yield of only 0.21%, and free cash flow of ₹64 Cr against a market cap of ₹9,868 Cr, the cash returned to shareholders is minuscule. This is a fast grower and a good company, but not a good investment at today's price. I would wait for a lower price or evidence that profits start growing in line with sales.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer